Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Kezar Life Sciences, Inc.

$7.29

-0.07 (-0.95%)

D 29Pipeline Score Richly Valued Biotech · Clinical
Market Cap
53.86 M
EPS
-6.18
P/E Ratio
-
Value Trade
4.51 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • R&D Expenses

    1.54 M

  • Operating CF

    -7.45 M

  • Total Assets

    68.00 M

  • Total Liabilities

    2.76 M

  • Equity

    65.24 M

  • D/E Ratio

    12,345

0.41 %
Week
-1.75 %
1 Month
20.9 %
3 Month
19.51 %
6 Month
-86.6 %
5 Year
-96.36 %
All Time
Cash Data
Healthy

  • Cash Position

    66.23 M

  • Monthly Burn

    2.48 M

  • Runway

    24.8 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 11, 2026
Overview
Volume
616.01 K
52 Week Range
3.53 - 7.55
% held by Insiders
17.37 %
% held by Institutions
60.37 %
Enterprise Value
-11.02 M
Total Shares
7.33 M
Short %
3.05 %
Float Shares
5.20 M
Company Description
HQ: 4000 SHORELINE COURT, SUITE 30...
Employees:55
https://www.kezarlifesciences....

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
Unlock Historical Catalyst data
Drug Pipeline Intelligence
D29
Pipeline Score
$4M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 33%
Micro Cap
(rank 612 of 912)
Percentile Rank
Kezar Life Sciences, Inc. faces pipeline headwinds (29/100), with $70M risk-adjusted pipeline value, led by zetomipzomib in Autoimmune Hepatitis (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
zetomipzomib
Small molecule		Autoimmune HepatitisPhase 2NCT0556975921% $64M COMPLETED 24 - -Apr 30, 2025 -Jan 13, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Zetomipzomib
Autoimmune Hepatitis (AIH)
Phase 2a
2025-03-25

36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg day or less, compared to 0 of 7 of placebo patients; 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper ( 5 mg day), compared to 1 of 8 placebo patients; Median duration of response in zetomipzomib patients achieving a CR was 27.6 weeks

Read More

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Fi

Read More
Zetomipzomib
Autoimmune Hepatitis (AIH)
Phase 2a
2025-03-25

36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg day or less, compared to 0 of 7 of placebo patients; 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper ( 5 mg day), compared to 1 of 8 placebo patients; Median duration of response in zetomipzomib patients achieving a CR was 27.6 weeks

Read More

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Fi

Read More
Zetomipzomib
Autoimmune Hepatitis (AIH)
Phase 2a
2025-03-25

36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg day or less, compared to 0 of 7 of placebo patients; 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper ( 5 mg day), compared to 1 of 8 placebo patients; Median duration of response in zetomipzomib patients achieving a CR was 27.6 weeks

Read More

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Fi

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in KZR
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
KZR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How KZR ranks across every disease it competes in
Competitive Position is a premium feature
See how KZR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial